NCT06789172 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT06789172
Title	A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors (INVOKE)
Acronym	INVOKE
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Epkin
Indications	fibrosarcoma laryngeal squamous cell carcinoma lung squamous cell carcinoma lung non-small cell carcinoma colorectal cancer pancreatic adenocarcinoma oral cavity cancer oropharynx cancer Advanced Solid Tumor head and neck squamous cell carcinoma malignant fibrous histiocytoma hypopharynx cancer dedifferentiated liposarcoma myxofibrosarcoma
Therapies	OKN4395 + Pembrolizumab OKN4395 Famotidine + OKN4395
Age Groups:	senior \| adult
Covered Countries	USA \| GBR \| AUS

Additional content available in CKB BOOST